Unknown

Dataset Information

0

Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs.


ABSTRACT: The sustained cell proliferation resulting from dysregulation of the cell cycle and activation of cyclin-dependent kinases (CDKs) is a hallmark of cancer. The inhibition of CDKs is a highly promising and attractive strategy for the development of anticancer drugs. In particular, third-generation CDK inhibitors can selectively inhibit CDK4/6 and regulate the cell cycle by suppressing the G1 to S phase transition, exhibiting a perfect balance between anticancer efficacy and general toxicity. To date, three selective CDK4/6 inhibitors have received approval from the U.S. Food and Drug Administration (FDA), and 15 CDK4/6 inhibitors are in clinical trials for the treatment of cancers. In this perspective, we discuss the crucial roles of CDK4/6 in regulating the cell cycle and cancer cells, analyze the rationale for selectively inhibiting CDK4/6 for cancer treatment, review the latest advances in highly selective CDK4/6 inhibitors with different chemical scaffolds, explain the mechanisms associated with CDK4/6 inhibitor resistance and describe solutions to overcome this issue, and briefly introduce proteolysis targeting chimera (PROTAC), a new and revolutionary technique used to degrade CDK4/6.

SUBMITTER: Yuan K 

PROVIDER: S-EPMC7838032 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs.

Yuan Kai K   Wang Xiao X   Dong Haojie H   Min Wenjian W   Hao Haiping H   Yang Peng P  

Acta pharmaceutica Sinica. B 20200523 1


The sustained cell proliferation resulting from dysregulation of the cell cycle and activation of cyclin-dependent kinases (CDKs) is a hallmark of cancer. The inhibition of CDKs is a highly promising and attractive strategy for the development of anticancer drugs. In particular, third-generation CDK inhibitors can selectively inhibit CDK4/6 and regulate the cell cycle by suppressing the G1 to S phase transition, exhibiting a perfect balance between anticancer efficacy and general toxicity. To da  ...[more]

Similar Datasets

| S-EPMC8698907 | biostudies-literature
2023-07-07 | GSE236502 | GEO
| S-EPMC7267102 | biostudies-literature
| S-EPMC3343382 | biostudies-literature
| S-EPMC8945444 | biostudies-literature
2014-01-07 | E-GEOD-53872 | biostudies-arrayexpress
2014-01-07 | GSE53872 | GEO
| S-EPMC6017514 | biostudies-literature
| S-EPMC6171565 | biostudies-literature
| S-EPMC5454392 | biostudies-literature